Dominari Holdings Inc. (NASDAQ:DOMH) Sees Large Growth in Short Interest

Dominari Holdings Inc. (NASDAQ:DOMH) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 952,800 shares, a growth of 232.0% from the January 31st total of 287,000 shares. Currently, 30.6% of the company’s stock are sold short. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is presently 0.6 days.

Institutional Trading of Dominari

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC boosted its holdings in Dominari Holdings Inc. (NASDAQ:DOMH) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,326 shares of the company’s stock after acquiring an additional 9,400 shares during the period. Renaissance Technologies LLC owned about 0.89% of Dominari worth $55,000 at the end of the most recent quarter. 42.48% of the stock is currently owned by institutional investors and hedge funds.

Dominari Trading Down 2.6 %

NASDAQ DOMH traded down $0.20 on Friday, hitting $7.57. 180,790 shares of the stock traded hands, compared to its average volume of 2,456,141. The stock has a 50-day moving average of $3.81 and a 200 day moving average of $2.44. Dominari has a twelve month low of $0.83 and a twelve month high of $13.58. The company has a market capitalization of $47.96 million, a P/E ratio of -1.96 and a beta of 1.25.

Dominari Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, March 3rd. Shareholders of record on Monday, February 24th will be issued a $0.32 dividend. The ex-dividend date is Monday, February 24th.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.